Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NEW PRODUCTS
April 26, 2004
- WORLD NEWS IN BRIEF
April 26, 2004
- Annual Business Results
April 26, 2004
- BI Aims at 1 Bil. Euro in Sales of Spiriva as Soon as Possible: Dr Heil
April 26, 2004
- 1st Qtr Business Results
April 26, 2004
- Gatiflo 0.3% Ophthalmic Solution Recommended for Approval
April 26, 2004
- Application Review, Safety Measures Are PMDA's Main Roles: Director Miyajima
April 26, 2004
- REGULATORY NEWS IN BRIEF
April 26, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 26, 2004
- Selection of Antibacterials Taking Resistant Strains into Account Recommended: JAID Meeting
April 26, 2004
- Kyowa Hakko Distributes Poster to Prevent Errors in Dispensing Allelock
April 19, 2004
- ACCJ's Recommendation on Medical Devices Published
April 19, 2004
- 8.5% of Patients Using Generic Statins: EPOCA Survey
April 19, 2004
- MEDICAL DEVICE NEWS IN BRIEF
April 19, 2004
- Dainippon Introduces Performance-based Personnel System
April 19, 2004
- Combined Sales of JCROA Member Companies to Exceed \50 Bil. in 2004: Mr Nakamura
April 19, 2004
- BUSINESS NEWS IN BRIEF
April 19, 2004
- BULLETIN
April 19, 2004
- Website News
April 19, 2004
- PMDA to Expedite NDA Review Process, Strengthen Safety Measures
April 19, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…